Medicine and Dentistry
Transitional Cell Carcinoma
100%
Nephroureterectomy
66%
Bladder
34%
Recurrent Disease
33%
Overall Survival
30%
Cohort Analysis
25%
Cancer Specific Survival
24%
Prostate Cancer
24%
Urothelial Cancer
24%
Disease Free Survival
21%
Upper Urinary Tract
21%
Inguinal Hernia
20%
Urinary System
20%
Symptom
18%
Neoplasm
16%
Recurrence Free Survival
15%
Bladder Cancer
15%
Uropathogenic Escherichia Coli
14%
Hydronephrosis
13%
Treatment Response
11%
Hernioplasty
11%
Malignant Neoplasm
11%
Cardiovascular Disease
11%
Hazard Ratio
11%
Herniorrhaphy
10%
Signal Transduction
10%
Erectile Dysfunction
10%
Adjuvant Chemotherapy
10%
Ureter Tumor
10%
Infection
10%
Urinary Tract
10%
Prognostic Factor
10%
Meta-Analysis
9%
Prostate Cell
9%
Percutaneous Nephrolithotomy
9%
Methylation
9%
Clear Cell Renal Cell Carcinoma
9%
Randomized Clinical Trial
9%
Proportional Hazards Model
9%
Hernia
8%
Survival Rate
8%
Stent Placement
8%
Metastatic Carcinoma
8%
Disease
8%
Prevalence
8%
Postoperative Complication
7%
Chronic Kidney Disease
7%
Pelvic Tumor
7%
Subgroup Analysis
7%
Operation Duration
7%
Pharmacology, Toxicology and Pharmaceutical Science
Transitional Cell Carcinoma
59%
Prostate Cancer
24%
Recurrent Disease
18%
Malignant Neoplasm
16%
Neoplasm
16%
Renal Cell Carcinoma
14%
Uropathogenic Escherichia Coli
14%
Cigarette Smoking
14%
Tumor Necrosis Factor
13%
Overall Survival
12%
Bladder Cancer
12%
Androgen
10%
Chemotherapy
10%
Interleukin 8
9%
Infection
9%
Castration Resistant Prostate Cancer
9%
Case-Control Study
9%
Arginine
8%
Disease Exacerbation
7%
Prostate Specific Antigen
7%
Disease
7%
Inflammation
6%
Enzalutamide
5%
Cardiovascular Disease
5%
Pelvis Pain Syndrome
5%
Biochemistry, Genetics and Molecular Biology
Uropathogenic Escherichia Coli
14%
Tumor Necrosis Factor
12%
Genotyping
11%
Passive Smoking
11%
Signal Transduction
10%
Interleukin 8
10%
Gene Promoter
9%
Tumor Necrosis Factor Alpha
9%
Case-Control Study
8%
Cigarette Smoking
8%
Overall Survival
8%
Prostate-Specific Antigen
7%
Tumor Volume
7%
STAT1
7%
Enzalutamide
5%
Upregulation
5%
Anticancer
5%